Clinical Trials Logo

Filter by:
NCT ID: NCT05707767 Recruiting - Surgery Clinical Trials

A Prospective Study of Surgical Treatment Strategies for Chordoma

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

Chordoma is a rare but locally invasive cancer that arises from the embryonic notochord. Total resection is challenging in mobile spine because of the complex anatomy and bone invasion.

NCT ID: NCT05707676 Recruiting - Solid Tumor Clinical Trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors(MEETCD8-001)

MEETCD8-001
Start date: November 30, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase I study designed to evaluate if LB4330, an anti-Claudin 18.2 and CD8 T cell activator fusion protein, is safe, tolerable and efficacious in participants with Advanced Solid Tumors

NCT ID: NCT05707585 Recruiting - Lung Cancer Clinical Trials

Lung Cancer Diagnosis by Detecting Epigenetic Imprinting Alterations in Bronchoalveolar Lavage

Start date: January 29, 2023
Phase:
Study type: Observational

The goal of this multicenter observational study is to evaluate the lung cancer diagnostic value of epigenetic imprinting detection in bronchoalveolar lavage. This study will mainly focus on varifing the previously identified epigenetic imprinting biomarkers for lung cancer and upgrading and validating a lung cancer imprinting diagnostic model specifically for bronchoalveolar lavage. The lavage sample will be collected from each eligible paticipants under bronchialscopy and undergo QCIGISH detection to analyze the allelic expression status of imprinted genes. The QCIGISH detection results will be compared with the final surgical histopathology. No interventions will be taken according to the QCIGISH detection results.

NCT ID: NCT05707520 Recruiting - Clinical trials for Liver Transplant Rejection

Long-term Benefit of MPA in Liver Transplantation

Start date: December 4, 2022
Phase:
Study type: Observational

MPA drugs are antiproliferative immunosuppressants and are widely used in solid organ transplantation. MPA drugs do not affect the recipient's kidney function and do not cause metabolic abnormalities and other problems. Intestinal solvent-based MPA drugs are widely used in clinical practice by improving the dosage form, reducing the irritation of MPA to the mucosa of the digestive tract, improving the tolerability of patients and maintaining a sufficient amount of MPA. However, data on the use/long-term use of intestinal solvent-based MPAs in liver transplant recipients are lacking. The study aims to evaluate the long-term benefits of enteric-coated mycophenolic acid in liver transplant recipients.

NCT ID: NCT05707442 Recruiting - Clinical trials for Venous Sinus Stenosis

Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE)

Start date: October 31, 2022
Phase: Phase 3
Study type: Interventional

The aim of this study is to assess the efficacy of stent implantation versus medical therapy on idiopathic intracranial hypertension with venous sinus stenosis.

NCT ID: NCT05707377 Recruiting - Clinical trials for Primary Membranous Nephropathy

A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy

Start date: April 17, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropathy who are on optimal supportive care.

NCT ID: NCT05707325 Recruiting - Cancer Clinical Trials

Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies

Reboot-101
Start date: October 31, 2022
Phase: Phase 1
Study type: Interventional

This phase studies the engineered red blood cells with PD-1 inhibitor pembrolizumab(WTX212), the natural biological metabolic function of red blood cells can make the carried pembrolizumab directionally distributed in the spleen tissue and activitate T cells, suggesting that this product may solve the problem that PD-1 treatment failure.

NCT ID: NCT05706415 Recruiting - Clinical trials for AI Assist in the Diagnosis of Pancreatic Solid Lesions

AI Assisted the Diagnosis of Pancreatic Solid Lesions

Start date: January 21, 2023
Phase:
Study type: Observational

Solid lesions of the pancreas mainly include tumor and non tumor lesions. More than 90% of pancreatic tumor lesions are pancreatic cancer, which is characterized by high mortality and poor prognosis and requires surgical treatment; Non-tumor lesions of the pancreas are mainly inflammatory lesions, which usually do not require surgical treatment, but can be treated with drugs. The common ones are chronic pancreatitis and autoimmune pancreatitis, with a good prognosis. Clinically, the differential diagnosis between them is very difficult. Multi-disciplinary diagnosis and treatment of MDT makes our understanding of pancreatic diseases increasingly rich and in-depth. From disease diagnosis to preoperative evaluation and curative effect evaluation, non-invasive imaging involves almost every link under MDT mode. In view of this, improving the differential diagnosis of pancreatic solid space-occupying lesions on imaging will be more conducive to the diagnosis and treatment under MDT mode, so new technologies such as artificial intelligence should be considered. Our goal is to develop a clinically applicable artificial intelligence system, which uses multiple modes to simulate the routine clinical workflow and assist in the diagnosis of benign and malignant pancreatic solid space-occupying lesions.

NCT ID: NCT05706207 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of HB0030 Injection in Patients With Advanced Solid Tumors

Start date: December 21, 2021
Phase: Phase 1
Study type: Interventional

This is a phase Ia single-center, open-label, dose escalation study.The objectives of this study are to evaluate the safety, toxicity, tolerability, pharmacokinetics/pharmacodynamics(PK/PD), immunogenicity, biomarkers, and antitumor activity of HB0030 in advanced solid tumor subjects.

NCT ID: NCT05705856 Recruiting - Crohn Disease Clinical Trials

Effectiveness and Safety of Ustekinumab Intensification in Crohn's Disease

Start date: February 15, 2023
Phase:
Study type: Observational

The primary purpose of this study is to evaluate the efficacy and safety of intravenous administration at regular intervals of Ustekinumab in participants with loss of response to standard regimen or have evidence of high activity clinically, biochemically or endoscopically.